Overview

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

Status:
Completed
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
Phase:
Phase 3
Details
Lead Sponsor:
Shire